On Invalid Date, Janux Therapeutics (NASDAQ: JANX) reported Q4 2023 earnings per share (EPS) of -$0.24, up 38.46% year over year. Total Janux Therapeutics earnings for the quarter were -$11.76 million. In the same quarter last year, Janux Therapeutics's earnings per share (EPS) was -$0.39.
As of Q1 2024, Janux Therapeutics's earnings has grown year over year. Janux Therapeutics's earnings in the past year totalled -$58.29 million.
What is JANX's earnings date?
Janux Therapeutics's earnings date is Invalid Date. Add JANX to your watchlist to be reminded of JANX's next earnings announcement.
What was JANX's revenue last quarter?
On Invalid Date, Janux Therapeutics (NASDAQ: JANX) reported Q4 2023 revenue of $2.46 million up 13.5% year over year. In the same quarter last year, Janux Therapeutics's revenue was $2.85 million.
What was JANX's revenue growth in the past year?
As of Q1 2024, Janux Therapeutics's revenue has grown -6.14% year over year. This is 175.44 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Janux Therapeutics's revenue in the past year totalled $8.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.